Skip to main content
. 2021 May 14;13(5):722. doi: 10.3390/pharmaceutics13050722

Figure 4.

Figure 4

Graphical illustration of CTCAE grades for thrombocytopenia, leukocytopenia, anemia, renal function impairment and xerostomia at baseline (upper row) and after two cycles of [177Lu]Lu-PSMA-617 RLT with at least one [225Ac]Ac-PSMA-617 augmentation (lower row).